Display options
Cite
Chapman BV, Liu D, Shen Y, et al. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys. 2021;112(2):437-444doi: 10.1016/j.ijrobp.2021.09.026.
Chapman, B. V., Liu, D., Shen, Y., Olamigoke, O. O., Lakomy, D. S., Barrera, A. M. G., Stecklein, S. R., Sawakuchi, G. O., Bright, S. J., Bedrosian, I., Litton, J. K., Smith, B. D., Woodward, W. A., Perkins, G. H., Hoffman, K. E., Stauder, M. C., Strom, E. A., Arun, B. K., & Shaitelman, S. F. (2022). Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. International journal of radiation oncology, biology, physics, 112(2), 437-444. https://doi.org/10.1016/j.ijrobp.2021.09.026
Chapman, Bhavana V, et al. "Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing." International journal of radiation oncology, biology, physics vol. 112,2 (2022): 437-444. doi: https://doi.org/10.1016/j.ijrobp.2021.09.026
Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys. 2022 Feb 01;112(2):437-444. doi: 10.1016/j.ijrobp.2021.09.026. Epub 2021 Sep 25. PMID: 34582940.
Copy Download .nbib Format: NLM
Share it on

Int J Radiat Oncol Biol Phys. 2022 Feb 01;112(2):437-444. doi: 10.1016/j.ijrobp.2021.09.026. Epub 2021 Sep 25.

Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.

International journal of radiation oncology, biology, physics

Bhavana V Chapman, Diane Liu, Yu Shen, Oluwafikayo O Olamigoke, David S Lakomy, Angelica M Gutierrez Barrera, Shane R Stecklein, Gabriel O Sawakuchi, Scott J Bright, Isabelle Bedrosian, Jennifer K Litton, Benjamin D Smith, Wendy A Woodward, George H Perkins, Karen E Hoffman, Michael C Stauder, Eric A Strom, Banu K Arun, Simona F Shaitelman

Affiliations

  1. Departments of Radiation Oncology.
  2. Biostatistics.
  3. Breast Medical Oncology and Clinical Cancer Genetics.
  4. Radiation Physics, and.
  5. Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  6. Departments of Radiation Oncology. Electronic address: [email protected].

PMID: 34582940 DOI: 10.1016/j.ijrobp.2021.09.026

Abstract

PURPOSE: Multigene panel testing has increased the detection of germline mutations in patients with breast cancer. The implications of using radiation therapy (RT) to treat patients with pathogenic variant (PV) mutations are not well understood and have been studied mostly in women with only BRCA1 or BRCA2 PVs. We analyzed oncologic outcomes and toxicity after adjuvant RT in a contemporary, diverse cohort of patients with breast cancer who underwent genetic panel testing.

METHODS AND MATERIALS: We retrospectively reviewed the records of 286 women with clinical stage I-III breast cancer diagnosed from 1995 to 2017 who underwent surgery, breast or chest wall RT with or without regional nodal irradiation, multigene panel testing, and evaluation at a large cancer center's genetic screening program. We evaluated rates of overall survival, locoregional recurrence, disease-specific death, and radiation-related toxicities in 3 groups: BRCA1/2 PV carriers, non-BRCA1/2 PV carriers, and patients without PV mutations.

RESULTS: PVs were detected in 25.2% of the cohort (12.6% BRCA1/2 and 12.6% non-BRCA1/2). The most commonly detected non-BRCA1/2 mutated genes were ATM, CHEK2, PALB2, CDH1, TP53, and PTEN. The median follow-up time for the entire cohort was 4.4 years (95% confidence interval, 3.8-4.9 years). No differences were found in overall survival, locoregional recurrence, or disease-specific death between groups (P > .1 for all). Acute and late toxicities were comparable across groups.

CONCLUSION: Oncologic and toxicity outcomes after RT in women with PV germline mutations detected by multigene pane testing are similar to those in patients without detectable mutations, supporting the use of adjuvant RT as a standard of care when indicated.

Copyright © 2021 Elsevier Inc. All rights reserved.

Publication Types

Grant support